ATE313318T1 - Trockenpulverzusammensetzungen mit verbesserter dispersität - Google Patents

Trockenpulverzusammensetzungen mit verbesserter dispersität

Info

Publication number
ATE313318T1
ATE313318T1 AT00922117T AT00922117T ATE313318T1 AT E313318 T1 ATE313318 T1 AT E313318T1 AT 00922117 T AT00922117 T AT 00922117T AT 00922117 T AT00922117 T AT 00922117T AT E313318 T1 ATE313318 T1 AT E313318T1
Authority
AT
Austria
Prior art keywords
dry powder
powder compositions
formulation
tripeptide
lung
Prior art date
Application number
AT00922117T
Other languages
English (en)
Inventor
David Lechuga-Ballesteros
Mei-Chang Kuo
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Application granted granted Critical
Publication of ATE313318T1 publication Critical patent/ATE313318T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
AT00922117T 1999-10-29 2000-04-12 Trockenpulverzusammensetzungen mit verbesserter dispersität ATE313318T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US16245199P 1999-10-29 1999-10-29
US16423699P 1999-11-08 1999-11-08
US17276999P 1999-12-20 1999-12-20
US17841500P 2000-01-27 2000-01-27
US17838300P 2000-01-27 2000-01-27
PCT/US2000/009785 WO2001032144A1 (en) 1999-10-29 2000-04-12 Dry powder compositions having improved dispersivity

Publications (1)

Publication Number Publication Date
ATE313318T1 true ATE313318T1 (de) 2006-01-15

Family

ID=27538661

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05027610T ATE461692T1 (de) 1999-10-29 2000-04-12 Trockenpulverzusammensetzungen mit verbesserter dispersität
AT00922117T ATE313318T1 (de) 1999-10-29 2000-04-12 Trockenpulverzusammensetzungen mit verbesserter dispersität

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT05027610T ATE461692T1 (de) 1999-10-29 2000-04-12 Trockenpulverzusammensetzungen mit verbesserter dispersität

Country Status (21)

Country Link
US (4) US6518239B1 (de)
EP (2) EP1223915B1 (de)
JP (2) JP4859320B2 (de)
KR (1) KR100702878B1 (de)
CN (1) CN1188111C (de)
AT (2) ATE461692T1 (de)
AU (1) AU775565B2 (de)
CA (1) CA2389219C (de)
CY (1) CY1110136T1 (de)
DE (2) DE60044070D1 (de)
DK (2) DK1666028T3 (de)
ES (2) ES2254164T3 (de)
HK (1) HK1092687A1 (de)
HU (1) HU229310B1 (de)
IL (2) IL149085A0 (de)
MX (1) MXPA02004193A (de)
NO (1) NO332144B1 (de)
NZ (1) NZ518401A (de)
PT (1) PT1666028E (de)
TW (1) TWI310688B (de)
WO (1) WO2001032144A1 (de)

Families Citing this family (239)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6231851B1 (en) * 1994-05-18 2001-05-15 Inhale Therapeutic Systems Methods and compositions for the dry powder formulation of interferons
US6673335B1 (en) * 1992-07-08 2004-01-06 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized medicaments
ATE220327T1 (de) * 1992-09-29 2002-07-15 Inhale Therapeutic Syst Pulmonale abgabe von aktiven fragmenten des parathormons
AU689217B2 (en) * 1994-03-07 1998-03-26 Novartis Ag Methods and compositions for pulmonary delivery of insulin
US20030113273A1 (en) * 1996-06-17 2003-06-19 Patton John S. Methods and compositions for pulmonary delivery of insulin
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6428771B1 (en) * 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
US20030035778A1 (en) * 1997-07-14 2003-02-20 Robert Platz Methods and compositions for the dry powder formulation of interferon
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
GB9827145D0 (en) * 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
US6858199B1 (en) * 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
PT1808438E (pt) * 1999-06-29 2015-01-14 Mannkind Corp Purificação e estabilização de péptidos e proteínas em agentes farmacêuticos
US9006175B2 (en) * 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
CA2387016C (en) 1999-10-08 2010-09-28 William H. Miller Acrylamide derivatives as fab i inhibitors
NZ518401A (en) 1999-10-29 2004-01-30 Nektar Therapeutics Dry powder compositions having improved dispersivity
US8820316B2 (en) * 2000-02-11 2014-09-02 Respironics Respiratory Drug Delivery (Uk) Ltd Drug delivery apparatus
WO2001058514A1 (en) * 2000-02-11 2001-08-16 Profile Respiratory Systems Limited Drug delivery apparatus
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
US8404217B2 (en) * 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
EP1913939B1 (de) 2000-06-27 2017-05-31 Vectura Limited Formulierungen zur Verwendung in Inhalationsvorrichtungen
WO2002009674A2 (en) * 2000-07-28 2002-02-07 Inhale Therapeutic Systems, Inc. Methods and compositions to upregulate, redirect or limit immune responses to bioactive compounds
EP1309312A2 (de) * 2000-08-07 2003-05-14 Inhale Therapeutic Systems, Inc. Inhalierbare sprühgetrocknete pulver aus proteinen die bündel aus 4 helices ausbilden mit minimierter aggregation
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
WO2002054868A2 (en) * 2000-12-21 2002-07-18 Inhale Therapeutic Syst Pulmonary delivery of polyene antifungal agents
US7138419B2 (en) * 2000-12-27 2006-11-21 Corus Pharma, Inc. Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate
US20020114843A1 (en) * 2000-12-27 2002-08-22 Ramstack J. Michael Preparation of microparticles having improved flowability
DK2301524T3 (da) * 2000-12-27 2013-07-15 Gilead Sciences Inc Inhalerbar aztreonam uden arginin til behandling og forebyggelse af bakterielle lungeinfektioner
US7214364B2 (en) 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
EP1560584B1 (de) * 2001-04-06 2009-01-14 Affinium Pharmaceuticals, Inc. Fab-i-inhibitoren
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
WO2002094229A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of muscle relaxants through an inhalation route
EP1392262A1 (de) * 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Verabreichung von arzneimittel-estern durch inhalation
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
EG24184A (en) * 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
WO2002103018A1 (fr) * 2001-06-15 2002-12-27 Takeda Chemical Industries, Ltd. Nouveau polypeptide et son utilisation
WO2003035028A1 (en) * 2001-10-19 2003-05-01 Nektar Therapeutics Modulating charge density to produce improvements in the characteristics of spray-dried proteins
WO2003035051A2 (en) * 2001-10-19 2003-05-01 Inhale Therapeutic Systems, Inc. The use of proton sequestering agents in drug formulations
AUPR879601A0 (en) * 2001-11-09 2001-12-06 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
DK1458360T3 (da) * 2001-12-19 2011-08-29 Novartis Ag Pulmonær afgivelse af aminoglycosider
US6900317B2 (en) 2002-02-19 2005-05-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
DE10206770A1 (de) * 2002-02-19 2003-08-28 Boehringer Ingelheim Pharma Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096
DE10207026A1 (de) * 2002-02-20 2003-08-28 Boehringer Ingelheim Kg Pulverinhalativum, enthaltend den CGRP-Antagonisten BIBN4096 und Verfahren zu dessen Herstellung
US20040014679A1 (en) * 2002-02-20 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co., Kg Inhalation powder containing the CGRP antagonist BIBN4096 and process for the preparation thereof
US6923175B2 (en) * 2002-03-20 2005-08-02 Mannkind Corporation Inhalation apparatus
EP1487411B1 (de) * 2002-03-20 2019-01-02 Civitas Therapeutics, Inc. Inhalierbare therapeutische depot-formulierungen
GB0216562D0 (en) * 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
US7285269B2 (en) * 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
DK1575951T3 (da) * 2002-12-06 2014-09-15 Debiopharm Int Sa Heterocykliske forbindelser, fremgangsmåder til fremstilling deraf og deres anvendelse i terapi
TWI327073B (en) * 2002-12-13 2010-07-11 Otsuka Pharma Co Ltd Dry powder inhale system for pulmonary administration
JP2004238392A (ja) * 2003-01-14 2004-08-26 Nipro Corp 安定化された蛋白質性製剤
EP1594500B1 (de) * 2003-02-10 2010-09-29 Bayer Schering Pharma Aktiengesellschaft Behandlung bakterieller erkrankungen der atmungsorgane durch lokale applikation von fluorchinolonen
EP1608377B1 (de) 2003-03-17 2008-10-01 Affinium Pharmaceuticals, Inc. Pharmazeutische zusammensetzungen inhibitoren von fab i und weitere antibiotika enthaltend
JP2007524607A (ja) * 2003-04-09 2007-08-30 ワイス 凝固因子の吸入による血友病処置
WO2004096144A2 (en) * 2003-04-28 2004-11-11 3M Innovative Properties Company Compositions and methods for induction of opioid receptors
US20050079166A1 (en) 2003-05-21 2005-04-14 Alexza Molecular Delivery Corporation Self-contained heating unit and drug-supply unit employing same
EP1635786A2 (de) * 2003-05-28 2006-03-22 Nektar Therapeutics Sprühtrocknung einer alkoholischen wässrigen lösung zur herstellung eines wasserunlöslichen wirkstoff-mikroteilchens mit einem teilweisen oder kompletten aminosäure- und/oder phospholipid-überzug
WO2005018551A2 (en) * 2003-08-12 2005-03-03 3M Innovative Properties Company Oxime substituted imidazo-containing compounds
DE10339197A1 (de) * 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität
WO2005020999A1 (en) * 2003-08-27 2005-03-10 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
JP2007504269A (ja) * 2003-09-05 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー Ｃｄ５＋ｂ細胞リンパ腫の治療方法
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
EP1663164A2 (de) * 2003-09-15 2006-06-07 Vectura Limited Verfahren zur herstellung von pharmazeutischen zusammensetzungen
MXPA06003705A (es) * 2003-10-03 2006-06-20 3M Innovative Properties Co Imidazoquinolinas sustituidas con alcoxi.
US7544697B2 (en) * 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
US20090075980A1 (en) * 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
US7338171B2 (en) * 2003-10-27 2008-03-04 Jen-Chuen Hsieh Method and apparatus for visual drive control
JP2007511535A (ja) * 2003-11-14 2007-05-10 スリーエム イノベイティブ プロパティズ カンパニー ヒドロキシルアミン置換イミダゾ環化合物
CA2545774A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
MXPA06005910A (es) * 2003-11-25 2006-08-23 3M Innovative Properties Co Sistemas de anillo imidazo sustituido y metodos.
DE10358387A1 (de) * 2003-12-13 2005-07-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulver enthaltend niedermolekulares Dextran und Verfahren zu deren Herstellung
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
PT1694363E (pt) * 2003-12-16 2014-02-20 Nektar Therapeutics Composições monodispersas de naloxol peguilado
EP1701955A1 (de) * 2003-12-29 2006-09-20 3M Innovative Properties Company Arylalkenyl- und arylalkinylsubstituierte imidazochinoline
AU2004312508A1 (en) * 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
RU2390330C2 (ru) 2003-12-31 2010-05-27 Сайдекс, Инк. Ингаляционная препаративная форма, содержащая простой сульфоалкиловый эфир гамма-циклодекстрина и кортикостероид
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US7192919B2 (en) 2004-01-07 2007-03-20 Stelios Tzannis Sustained release compositions for delivery of pharmaceutical proteins
KR100985126B1 (ko) * 2004-01-12 2010-10-05 맨카인드 코포레이션 제2형 당뇨병에서 혈청 프로인슐린 수치의 감소 방법
US20080248999A1 (en) * 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
US20080090753A1 (en) * 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
DE602004023765D1 (de) * 2004-03-12 2009-12-03 Trinity College Dublin Magnetoresistives medium
ES2398838T3 (es) * 2004-03-12 2013-03-22 Biodel, Inc. Composiciones de suministro de fármacos de acción rápida
US8697873B2 (en) * 2004-03-24 2014-04-15 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
SE528121C2 (sv) * 2004-03-29 2006-09-05 Mederio Ag Preparering av torrpulver för på förhand uppmätt DPI
PT2708225T (pt) 2004-04-23 2019-05-21 Cydex Pharmaceuticals Inc Formulação de dpi contendo éter sulfoalquílicociclodextrina
US20060039985A1 (en) * 2004-04-27 2006-02-23 Bennett David B Methotrexate compositions
US7611709B2 (en) 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
US7723306B2 (en) 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
US7727962B2 (en) 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
PL1828167T3 (pl) 2004-06-04 2015-02-27 Debiopharm Int Sa Pochodne akryloamidu jako środki antybiotykowe
WO2005123080A2 (en) * 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006038923A2 (en) * 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US7915281B2 (en) * 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
US8026366B2 (en) * 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
UA91512C2 (ru) 2004-07-19 2010-08-10 Биокон Лимитед Коньюгати олигомеров инсулина, их композиция (варианты) и применение
WO2006033713A2 (en) * 2004-08-09 2006-03-30 Chiron Corporation Methods for ciprofloxacin inhalation
PL1786784T3 (pl) 2004-08-20 2011-04-29 Mannkind Corp Kataliza syntezy diketopiperazyn
EP1791542B1 (de) 2004-08-23 2015-05-20 Mannkind Corporation Diketopiperazinsalze für die arzneiabgabe
JPWO2006025395A1 (ja) * 2004-08-31 2008-05-08 慶彦 清水 キャリアフリーの細胞増殖因子を用いた慢性閉塞性肺疾患に対する医薬および処置システム
WO2006026760A2 (en) * 2004-09-02 2006-03-09 3M Innovative Properties Company 1-amino imidazo-containing compounds and methods
WO2007011396A2 (en) * 2004-10-29 2007-01-25 President And Fellows Of Harvard College Particles for treatment of pulmonary infection
WO2006063072A2 (en) * 2004-12-08 2006-06-15 3M Innovative Properties Company Immunomodulatory compositions, combinations and methods
EP1831226B1 (de) * 2004-12-30 2012-08-08 3M Innovative Properties Company Chirale tetracyklische verbindungen, die interferon biosyntheze induzieren
EP1831221B1 (de) 2004-12-30 2012-08-08 3M Innovative Properties Company Substituierte, chirale, fusionierte 1,2 imidazo-4,5-c-ringverbindungen
JP2008530022A (ja) * 2005-02-04 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫反応調節物質を含む水性ゲル処方物
CA2597587A1 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
EP1869043A2 (de) 2005-04-01 2007-12-26 Coley Pharmaceutical Group, Inc. Pyrazolopyridin-1,4-diamine und analoge davon
AU2006232375A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
US8546423B2 (en) 2005-05-18 2013-10-01 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US7838532B2 (en) 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
KR101488403B1 (ko) 2005-05-18 2015-02-04 엠펙스 파마슈티컬즈, 인코포레이티드 에어로졸화된 플루오로퀴놀론 및 이의 용도
US20070031342A1 (en) * 2005-06-22 2007-02-08 Nektar Therapeutics Sustained release microparticles for pulmonary delivery
DK1928423T3 (en) 2005-09-14 2016-02-29 Mannkind Corp A method for drug formulation based on increasing the affinity of the active substances to the crystalline microparticle surfaces
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US8084420B2 (en) * 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
WO2007041481A1 (en) * 2005-09-29 2007-04-12 Biodel, Inc. Rapid acting and prolonged acting insulin preparations
ITMI20051999A1 (it) 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
WO2007067416A2 (en) * 2005-12-05 2007-06-14 Affinium Pharmaceuticals, Inc. Heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
EP2364735A3 (de) 2005-12-16 2012-04-11 Nektar Therapeutics Verzweigte PEG-Kon jugate von GLP-1
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070178049A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
CA2641827A1 (en) * 2006-02-10 2007-08-16 Pari Pharma Gmbh Nebulised antibiotics for inhalation therapy
EP1986674A4 (de) * 2006-02-13 2009-11-11 Nektar Therapeutics Methioninhaltige protein- oder peptidzusammensetzungen sowie verfahren zu ihrer herstellung und verwendung
CA2642641A1 (en) * 2006-02-15 2007-08-23 Tika Laekemedel Ab Stable corticosteroid mixtures
RU2403059C2 (ru) 2006-02-22 2010-11-10 Маннкайнд Корпорейшн Способ улучшения фармацевтических свойств микрочастиц, содержащих дикетопиперазин и активный агент
MX2008013165A (es) * 2006-04-12 2009-01-29 Biodel Inc Formulaciones de combinacion de insulina de accion rapida y accion larga.
PT2029740E (pt) * 2006-05-31 2012-07-06 Genzyme Corp Utilização de polissacáridos para promoção de actividade enzimática
US7906506B2 (en) * 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
EP2054422B1 (de) 2006-07-20 2017-06-14 Debiopharm International SA Acrylamidderivate als fab-i-inhibitoren
FR2904532B1 (fr) * 2006-08-03 2012-10-19 Soc Extraction Principes Actif Composition dermatologique et/ou cosmetique contenant des polypeptides ou des peptides
WO2008025560A1 (en) * 2006-09-01 2008-03-06 Pari Pharma Gmbh Methods for taste masking of nebulised compositions for nasal and pulmonary inhalation therapy
JP5265545B2 (ja) * 2006-09-01 2013-08-14 シーエスエル、リミテッド 免疫応答を誘発または誘導する方法
EP3255045A1 (de) * 2007-02-16 2017-12-13 Debiopharm International SA Salze, prodrugs und polymorphe von fab i-inhibitoren
EP2121088B1 (de) 2007-03-09 2016-07-13 Alexza Pharmaceuticals, Inc. Erhitzungseinheit zur verwendung in einer arzneimittelabgabevorrichtung
EP2152304B1 (de) 2007-05-02 2018-08-22 The Regents of the University of Michigan Therapeutische zusammensetzungen in nanoemulsionsform und anwendungsverfahren dafür
CA2692053A1 (en) 2007-06-26 2008-12-31 Merck Sharp & Dohme Corp. Lyophilized anti-fungal composition
EP2211956A4 (de) 2007-10-10 2014-07-09 Parion Sciences Inc Abgabe von osmolyten mit einer nasenkanüle
CN101820904A (zh) * 2007-10-12 2010-09-01 Csl有限公司 引起针对大流行性流感病毒的免疫应答的方法
AU2009204309B2 (en) * 2008-01-04 2012-11-22 Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
WO2009120619A2 (en) * 2008-03-24 2009-10-01 Novartis Ag Nuclease compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions
WO2009143011A1 (en) * 2008-05-20 2009-11-26 Novartis Ag Antiviral compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions
TWI611818B (zh) 2008-06-13 2018-01-21 曼凱公司 用於藥物傳輸之乾粉吸入器及系統
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
JP5479465B2 (ja) 2008-06-20 2014-04-23 マンカインド コーポレイション 吸入努力をリアルタイムにプロファイルする対話式機器および方法
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
US20110166063A1 (en) * 2008-09-19 2011-07-07 Nektar Therapeutics Polymer conjugates of therapeutic peptides
EP2344200A2 (de) * 2008-09-19 2011-07-20 Nektar Therapeutics Modifizierte therapeutische peptide, herstellungsverfahren und verwendung
WO2010036945A2 (en) * 2008-09-26 2010-04-01 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
HUE038428T2 (hu) 2008-10-07 2018-10-29 Horizon Orphan Llc Aeroszol fluorokinolon készítmények javított farmakokinetika érdekében
CN102325532B (zh) 2008-10-07 2015-06-17 Mpex医药有限公司 用于减轻肺部炎症的左氧氟沙星吸入剂
WO2010057197A1 (en) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
WO2010105094A1 (en) 2009-03-11 2010-09-16 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
JP5671001B2 (ja) 2009-03-26 2015-02-18 パルマトリックス，インコーポレイテッド 肺疾患を治療するための乾燥粉末製剤および方法
US9539233B2 (en) * 2009-05-04 2017-01-10 Aridis Pharmaceuticals Inc. Gallium formulation for the treatment and prevention of infectious diseases
TWI792140B (zh) 2009-05-29 2023-02-11 美商沛爾醫療股份有限公司 用於經由呼吸道遞送二或更多種活性藥劑的組成物、方法與系統
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
JP5908397B2 (ja) 2009-06-09 2016-04-26 デフィルス、インコーポレイテッドＤｅｆｙｒｕｓ， Ｉｎｃ． 病原体感染を予防又は治療するためのインターフェロン投与
US8734845B2 (en) 2009-06-12 2014-05-27 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
WO2011029059A1 (en) 2009-09-04 2011-03-10 Mpex Pharmaceuticals, Inc. Use of aerosolized levofloxacin for treating cystic fibrosis
CA2778698A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
WO2011063126A1 (en) * 2009-11-18 2011-05-26 Satoshi Ohtake Highly dispersible powders, compositions and methods for preparation
EP2533791B1 (de) * 2009-12-21 2017-01-25 Glanbia Nutritionals (Ireland) Ltd. Leucin-/peptidzusammensetzung und verfahren zur formulierung
EP3269805A1 (de) * 2010-04-20 2018-01-17 Octapharma AG Neues stabilisierungsmittel für pharmazeutische proteine
KR20130117755A (ko) 2010-06-21 2013-10-28 맨카인드 코포레이션 건조 분말 약물 운반 시스템 및 방법
WO2012030645A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
CN103200938B (zh) 2010-08-30 2018-07-31 普马特里克斯营业公司 干燥粉末配方及用于治疗肺部疾病的方法
KR101915241B1 (ko) 2010-09-29 2018-11-06 풀매트릭스 오퍼레이팅 컴퍼니, 인크 흡입용의 1가 금속 양이온 건조 분말
WO2012050945A1 (en) 2010-09-29 2012-04-19 Pulmatrix, Inc. Cationic dry powders
TW201233803A (en) 2010-12-02 2012-08-16 Oncolytics Biotech Inc Lyophilized viral formulations
AU2011336413B2 (en) 2010-12-02 2015-01-22 Oncolytics Biotech Inc. Liquid viral formulations
CN103429228B (zh) 2011-01-05 2016-10-26 赫士睿股份有限公司 万古霉素的喷雾干燥
WO2012106382A1 (en) 2011-01-31 2012-08-09 Genoa Pharmaceuticals, Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US10358043B2 (en) * 2011-03-31 2019-07-23 Elite Power Solutions, LLC Golf cart battery system
BR112013025395B1 (pt) 2011-04-01 2022-02-01 Mannkind Corporation Embalagem de bolha e método de fabricação de uma embalagem de bolhas
KR101763195B1 (ko) * 2011-05-19 2017-07-31 사바라 인코포레이티드 건조 분말 반코마이신 조성물 및 관련 방법
US9572774B2 (en) * 2011-05-19 2017-02-21 Savara Inc. Dry powder vancomycin compositions and associated methods
EP3170493B1 (de) 2011-06-07 2020-10-21 Asahi Kasei Pharma Corporation Gefriergetrocknetes präparat mit hochreinem pth und herstellungsverfahren dafür
CA2838529C (en) 2011-06-07 2020-03-24 Parion Sciences, Inc. Methods of treatment
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
CA2852536A1 (en) 2011-10-24 2013-05-02 Mannkind Corporation Methods and compositions for treating pain
RU2615076C2 (ru) 2011-12-16 2017-04-03 Новартис Аг Устройство аэрозолизации для независимой от профиля вдоха доставки лекарственного средства
EP2819672A1 (de) 2012-02-29 2015-01-07 Pulmatrix, Inc. Inhalierbare trockenpulver
KR101342485B1 (ko) * 2012-02-29 2013-12-17 미원상사주식회사 트리펩타이드 및 이를 함유하는 노화방지, 주름개선, 미백 및 항염효능의 화장료 조성물
US9707228B2 (en) * 2012-05-21 2017-07-18 Agency For Science, Technology And Research Dry powder formulation
PT2855435T (pt) 2012-05-29 2018-07-03 Parion Sciences Inc Aminoamidas do tipo dendrímeros possuindo atividade bloqueadora de canais de sódio para o tratamento do olho seco e outras doenças das mucosas
EA028136B1 (ru) 2012-06-19 2017-10-31 Дибиофарм Интернешнл Са Пролекарственные производные (е)-n-метил-n-((3-метилбензофуран-2-ил)метил)-3-(7-оксо-5,6,7,8-тетрагидро-1,8-нафтиридин-3-ил)акриламида
CN108057154B (zh) 2012-07-12 2021-04-16 曼金德公司 干粉药物输送系统和方法
EP2911690A1 (de) 2012-10-26 2015-09-02 MannKind Corporation Inhalierbare influenza-impfstoffzusammensetzungen und verfahren
MX2015007797A (es) 2012-12-17 2015-10-05 Parion Sciences Inc Compuestos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil) carbamimidoil) pirazin-2-carboxamida.
CA2896686A1 (en) 2012-12-17 2014-06-26 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
MX2015007796A (es) 2012-12-17 2015-09-04 Parion Sciences Inc Derivados de cloro-pirazin carboxamida con actividad bloqueadora sobre los canales de sodio epiteliales.
CN108578372B (zh) 2013-03-15 2021-07-06 曼金德公司 微晶二酮哌嗪组合物以及方法
US20140275517A1 (en) 2013-03-15 2014-09-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
KR20150135328A (ko) 2013-04-01 2015-12-02 풀매트릭스 인코퍼레이티드 티오트로피움 건조 분말
KR20160013134A (ko) 2013-05-22 2016-02-03 펄 테라퓨틱스 인코포레이티드 3 개 이상의 활성제의 호흡기 전달을 위한 조성물, 방법 및 시스템
JP6491658B2 (ja) * 2013-07-18 2019-03-27 マンカインド コーポレイション 熱安定性乾燥粉末医薬組成物及び方法
AU2014296032A1 (en) 2013-07-31 2016-03-17 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
CN105517607A (zh) 2013-08-05 2016-04-20 曼金德公司 吹入设备和方法
US9770443B2 (en) 2014-01-10 2017-09-26 Genoa Pharmaceuticals, Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
EP3204039B1 (de) 2014-10-10 2022-06-08 The Regents Of The University Of Michigan Nanoemulsionszusammensetzungen zur prävention, unterdrückung oder eliminierung von allergischen und entzündlichen erkrankungen
MY189221A (en) 2016-02-26 2022-01-31 Debiopharm Int Sa Medicament for treatment of diabetic foot infections
CA3023630A1 (en) * 2016-06-30 2018-01-04 Philip Morris Products S.A. Nicotine particles and compositions
US11479600B2 (en) 2016-10-21 2022-10-25 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
WO2018075974A2 (en) 2016-10-21 2018-04-26 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
KR102695416B1 (ko) 2016-10-21 2024-08-13 아디맵 엘엘씨 항-호흡기 세포융합 바이러스 항체, 그리고 이의 생성 방법 및 사용 방법
CN106727348B (zh) * 2016-12-20 2020-10-13 广州中大南沙科技创新产业园有限公司 防潮抗湿的低密度载体颗粒及其制备方法和应用
WO2018113891A1 (en) * 2016-12-23 2018-06-28 University Of Copenhagen A co-amorphous form of a substance and a dipeptide
CN114599348A (zh) * 2019-10-28 2022-06-07 阿斯利康(瑞典)有限公司 含亮氨酸和三亮氨酸的干粉配制品
AR120309A1 (es) * 2019-10-28 2022-02-09 Medimmune Ltd Formulaciones de polvo seco de anticuerpos que se unen a la linfopoyetina del estroma tímico (tslp) y métodos de uso de las mismas
CN116710104A (zh) * 2021-01-08 2023-09-05 江苏恒瑞医药股份有限公司 可通过定量吸入器递送的药物组合物
KR20240042437A (ko) 2021-07-09 2024-04-02 아스트라제네카 파마수티컬스 엘피 에어로졸 약물 전달을 위한 조성물, 방법 및 시스템
US20230053812A1 (en) * 2021-07-27 2023-02-23 Aurobindo Pharma Ltd Stable peptide formulations for oral use
WO2023091081A2 (en) * 2021-11-16 2023-05-25 Agency For Science, Technology And Research Inhalable recombinant protein powder formulation for treating genetic and autoimmune disorders
CN118414148A (zh) 2021-12-20 2024-07-30 阿斯利康(瑞典)有限公司 用于气溶胶药物递送的组合物、方法和系统
WO2023212191A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Combination of albuterol and budesonide for the treatment of asthma
WO2023229023A1 (ja) * 2022-05-25 2023-11-30 学校法人 名城大学 粉末剤及びその製造方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2224175B1 (de) * 1973-04-04 1978-04-14 Isf Spa
IT1017153B (it) * 1974-07-15 1977-07-20 Isf Spa Apparecchio per inalazioni
FR2519988B1 (fr) * 1982-01-20 1985-06-14 Refarmed Sa Derives thioliques de l'erythromycine a activite therapeutique, procede de preparation et produits pharmaceutiques dans lesquels ils apparaissent
SE438261B (sv) * 1981-07-08 1985-04-15 Draco Ab Anvendning i dosinhalator av ett perforerat membran
GB8314308D0 (en) 1983-05-24 1983-06-29 Matburn Holdings Ltd Medical administration devices
US4818542A (en) * 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US4805811A (en) * 1985-03-29 1989-02-21 Aktiebolaget Draco Dosage device
SE448277B (sv) * 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
US4668281A (en) * 1985-05-20 1987-05-26 E. I. Du Pont De Nemours And Company Thiophenesulfonamides
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
US5182258A (en) * 1989-03-20 1993-01-26 Orbon Corporation Systemic delivery of polypeptides through the eye
GB8909891D0 (en) 1989-04-28 1989-06-14 Riker Laboratories Inc Device
US5519049A (en) * 1989-06-06 1996-05-21 Fisons Plc Macrolides for the treatment of reversible obstructive airways diseases
US5376386A (en) 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
IT1243344B (it) 1990-07-16 1994-06-10 Promo Pack Sa Inalatore plurimonodose per medicamenti in polvere
ZA918014B (en) * 1990-11-05 1992-07-29 Squibb & Sons Inc Heteroaroyl derivatives of monocyclic beta-lactam antibiotics
ATE189124T1 (de) * 1991-07-02 2000-02-15 Inhale Inc Verfahren und vorrichtung zum abgeben von medikamenten in aerosolform
US5320094A (en) * 1992-01-10 1994-06-14 The Johns Hopkins University Method of administering insulin
ZA93929B (en) * 1992-02-18 1993-09-10 Akzo Nv A process for the preparation of biologically active materialcontaining polymeric microcapsules.
US6231851B1 (en) 1994-05-18 2001-05-15 Inhale Therapeutic Systems Methods and compositions for the dry powder formulation of interferons
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5785049A (en) * 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
GB2269992A (en) 1992-08-14 1994-03-02 Rh Ne Poulenc Rorer Limited Powder inhalation formulations
GB9218027D0 (en) 1992-08-25 1992-10-14 Fisons Plc Novel method of treatment
US5672581A (en) * 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
DE4323636A1 (de) 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
IS1736B (is) 1993-10-01 1999-12-30 Astra Ab Aðferð og tæki sem stuðla að aukinni samloðun agna
US5388572A (en) * 1993-10-26 1995-02-14 Tenax Corporation (A Connecticut Corp.) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
CN1318104C (zh) 1994-09-21 2007-05-30 耐科塔医药公司 送料管组件
US5522385A (en) * 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US5705482A (en) * 1995-01-13 1998-01-06 Novo Nordisk A/S Pharmaceutical formulation
KR19980703876A (ko) 1995-04-14 1998-12-05 스티븐 엘. 허스트 분산성이 개선된 분말화된 약학적 조성물
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US5654007A (en) * 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US5667068A (en) * 1995-06-13 1997-09-16 Weaver; Stevie W. Protective cover for an endoscope
GB9515182D0 (en) * 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
US20030138402A1 (en) * 1995-12-25 2003-07-24 Otsuka Pharmaceutical Co., Ltd. Dry compositions
TW403653B (en) 1995-12-25 2000-09-01 Otsuka Pharma Co Ltd Dry compositions
US5875776A (en) * 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
US5826633A (en) 1996-04-26 1998-10-27 Inhale Therapeutic Systems Powder filling systems, apparatus and methods
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
EP0971698A4 (de) * 1996-12-31 2006-07-26 Nektar Therapeutics Aerolisiertes hydrophobisches medikament
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
US6257233B1 (en) * 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
US6902721B1 (en) * 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
WO2000061178A1 (en) * 1999-04-13 2000-10-19 Inhale Therapeutics Systems, Inc. Pulmonary administration of dry powder formulations for treating infertility
AU779869B2 (en) * 1999-04-13 2005-02-17 Nektar Therapeutics Pulmonary administration of dry powder formulations for treating infertility
NZ518401A (en) * 1999-10-29 2004-01-30 Nektar Therapeutics Dry powder compositions having improved dispersivity

Also Published As

Publication number Publication date
CA2389219A1 (en) 2001-05-10
US20090117193A1 (en) 2009-05-07
IL149085A (en) 2007-05-15
US6835372B2 (en) 2004-12-28
EP1666028A1 (de) 2006-06-07
JP4859320B2 (ja) 2012-01-25
DE60044070D1 (de) 2010-05-06
CN1384733A (zh) 2002-12-11
NO332144B1 (no) 2012-07-02
EP1223915B1 (de) 2005-12-21
HUP0301851A3 (en) 2006-07-28
ES2254164T3 (es) 2006-06-16
HU229310B1 (en) 2013-10-28
DK1666028T3 (da) 2010-06-21
US7482024B2 (en) 2009-01-27
NO20021800D0 (no) 2002-04-17
JP2003513031A (ja) 2003-04-08
DE60025019T2 (de) 2006-08-24
DK1223915T3 (da) 2006-03-06
KR100702878B1 (ko) 2007-04-04
AU4235300A (en) 2001-05-14
ES2343124T3 (es) 2010-07-23
WO2001032144A1 (en) 2001-05-10
TWI310688B (en) 2009-06-11
AU775565B2 (en) 2004-08-05
NO20021800L (no) 2002-06-24
EP1223915A1 (de) 2002-07-24
DE60025019D1 (de) 2006-01-26
ATE461692T1 (de) 2010-04-15
CA2389219C (en) 2009-06-23
HUP0301851A2 (hu) 2003-09-29
US8501240B2 (en) 2013-08-06
JP2011093922A (ja) 2011-05-12
CN1188111C (zh) 2005-02-09
US20030186894A1 (en) 2003-10-02
MXPA02004193A (es) 2002-12-13
IL149085A0 (en) 2002-11-10
CY1110136T1 (el) 2015-01-14
US6518239B1 (en) 2003-02-11
PT1666028E (pt) 2010-06-15
HK1092687A1 (en) 2007-02-16
NZ518401A (en) 2004-01-30
US20050147567A1 (en) 2005-07-07
KR20020060218A (ko) 2002-07-16
EP1666028B1 (de) 2010-03-24

Similar Documents

Publication Publication Date Title
ATE313318T1 (de) Trockenpulverzusammensetzungen mit verbesserter dispersität
LV12586A (en) Aerosolized active agent delivery
AU3038197A (en) Aerosol formulations
CA2411754A1 (en) 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoic acid and compositions for delivering active agents
CA2346791A1 (en) Flow resistance modulated aerosolized active agent delivery
AU2001236207A1 (en) Powder formulation
BR9917089A (pt) Composições e métodos para distribuição mucosal
CA2295035A1 (en) Pharmaceutical formulations containing voriconazole
HK185596A (en) Non-chlorofluoro-carbon aerosol formulations
GR3018168T3 (en) Medicaments.
ZA9711732B (en) Methods and compositions for improvement bioavailability of bioactive agents for mucosal delivery
WO2000007979A3 (en) Compounds and compositions for delivering active agents
GB0016876D0 (en) Novel formulation
EP0882450A3 (de) Cholesterinsenkende Zusammensetzung enthaltend Coenzym Q
AU1251799A (en) Use of phospholipids for the manufacture of a medicament for the prevention of adhesions

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1223915

Country of ref document: EP